STATE-OF-THE-ART REVIEW

Fibroblasts in the Infarcted, Remodeling, and Failing Heart

Claudio Humeres, PhD, Nikolaos G. Frangogiannis, MD

HIGHLIGHTS

- Cardiac fibroblasts become activated following injury and participate in repair and remodeling of the heart.
- The authors discuss the phenotypic alterations and role of fibroblasts in infarcted and failing hearts.
- In failing hearts, fibroblasts may deposit ECM proteins, increasing myocardial stiffness, but may also exert protective and reparative actions.
- Future studies will focus on characterization of the phenotypic heterogeneity of cardiac fibroblasts that may explain their functional diversity.

SUMMARY

Expansion and activation of fibroblasts following cardiac injury is important for repair but may also contribute to fibrosis, remodeling, and dysfunction. The authors discuss the dynamic alterations of fibroblasts in failing and remodeling myocardium. Emerging concepts suggest that fibroblasts are not unidimensional cells that act exclusively by secreting extracellular matrix proteins, thus promoting fibrosis and diastolic dysfunction. In addition to their involvement in extracellular matrix expansion, activated fibroblasts may also exert protective actions, preserving the cardiac extracellular matrix, transducing survival signals to cardiomyocytes, and regulating inflammation and angiogenesis. The functional diversity of cardiac fibroblasts may reflect their phenotypic heterogeneity. (J Am Coll Cardiol Basic Trans Science 2019;4:449–67) © 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Most myocardial conditions are associated with “fibrosis,” expansion of the cardiac interstitium, due to deposition of extracellular matrix (ECM) proteins (1-3). In human patients with a wide variety of cardiac diseases, the extent of fibrotic changes is a strong predictor of adverse outcome. In patients with heart failure with reduced ejection fraction, and in those with heart failure with preserved ejection fraction, prominent fibrotic remodeling is associated with higher mortality, increased hospitalization rates, and an increased incidence of adverse cardiac events (4-7). Moreover, in subjects with diabetes, expansion of the myocardial interstitial space is associated with mortality and with heart failure hospitalizations (8). The association between fibrosis and poor prognosis may reflect the adverse functional consequences of ECM deposition on systolic and diastolic function or the proarrhythmic effects of fibrotic myocardial lesions. However, because the adult mammalian heart...
lacks significant endogenous regenerative capacity, cardiac fibrosis may also reflect activation of reparative mechanisms in response to primary cardiomyocyte injury. To what extent fibrotic cardiac remodeling represents a primary myocardial disease that mediates dysfunction and causes adverse outcome remains unknown.

Fibroblasts are the main effector cells of cardiac fibrosis. The adult mammalian heart contains abundant fibroblasts that expand following injury and can produce large amounts of ECM proteins. Animal model studies have identified cardiac fibroblasts both as critical reparative cells that maintain the structural integrity of the infarcted ventricle and as cellular effectors of heart failure that deposit stiff ECM in the interstitium, reducing myocardial compliance. The functional heterogeneity of fibroblast populations, their remarkable phenotypic plasticity, and the limited information on the characteristics and properties of fibroblasts in human myocardial diseases have hampered dissection of reparative and mal-adaptive fibroblast actions. In this review we describe the role of fibroblasts in failing and remodeling hearts. We discuss the dynamic alterations of fibroblasts in injury and repair of the infarcted heart and their role in remodeling and dysfunction of the ventricle in conditions associated with chronic heart failure.

The myocardium contains a large population of resident fibroblasts enmeshed within the ECM network (11,12). For many years, fibroblasts were considered the most abundant noncardiomyocytes in the adult mammalian myocardium. A study using flow cytometry in adult mice identified 27% of myocardial cells as discoidin domain–containing receptor 2-positive fibroblasts and only 7% of the cells as CD31+ endothelial cells (13), a finding quite surprising considering the high vascular content of the mammalian heart. In contrast, a more recent study using a combination of fibroblast reporter mouse models and cell-specific antibodies suggested that cardiac fibroblasts represent <20% of noncardiomyocytes and are greatly outnumbered by endothelial cells (which represent more than 60% of noncardiomyocytes) (14). Differences in the strategies used for cardiac cell isolation, and variability in the sensitivity and specificity of the methodological approaches used for cellular identification, may account, at least in part, for conflicting results in various investigations. Moreover, the relative numbers of various interstitial cell populations in the myocardium are also dependent on the age, sex, and species of the subjects studied. It should be emphasized that most of our knowledge on the characteristics of cardiac fibroblasts is based on studies in rodents, and relatively little is known regarding the density, phenotype, and distribution of fibroblasts in normal human hearts.

What is the function of resident fibroblasts in normal mammalian hearts? In the developing myocardium, cardiac fibroblasts have been suggested to regulate cardiomyocyte proliferation through a fibronectin/β1-integrin–mediated pathway (15). In adult hearts, normal cardiac function may require interactions between cardiomyocytes and the surrounding ECM. Cardiac fibroblasts, enmeshed into the endomysium and perimysium, may play an important role in regulation of the synthesis and turnover of ECM components, thus preserving the structural integrity of the ventricle (16-18). Mice with global germline loss of transcription factor 21, which is essential for cardiac fibroblast development, had greatly decreased collagen levels in the cardiac interstitium and exhibited dysmorphic hearts that lacked a distinct apex (19). Although these findings are consistent with an important role of fibroblasts in cardiac development, the consequences of fibroblast depletion on cardiac homeostasis in adult mice have not been investigated.

In addition to their critical role in the formation of the cardiac ECM network, fibroblasts may also contribute to cellular communication in the cardiac

Fibroblasts are defined and identified on the basis of functional and morphological criteria as cells of mesenchymal origin that lack a basement membrane and are involved in the formation and maintenance of connective tissues by producing a wide range of ECM proteins (9). Although several fibroblast markers have been proposed (Table 1), their specificity is limited. Moreover, considering that resident fibroblast populations in many tissues are heterogeneous (10) and undergo dynamic phenotypic changes following injury, identification of reliable markers that label all fibroblast subsets is a major challenge. Thus, characterization of fibroblasts typically requires the combined use of fibroblast-related markers (including ECM proteins that reflect their matrix-synthetic function) and exclusion criteria reflecting the absence of expression of endothelial, hematopoietic cell and vascular mural cell-specific proteins.
Fibroblasts exhibit remarkable phenotypic plasticity and undergo dramatic alterations in their gene expression profile and functional properties in response to mechanical stress or to stimulation with soluble mediators. In vitro, cardiac fibroblasts cultured in the low-tension environment of a collagen-based pad have dendritic morphology, synthesize low levels of collagen, and have negligible expression of PDGFRα, especially under conditions of stress (192), PDGFRα-GFP reporter lines seem to predominantly identify cells with fibroblast-like characteristics (193).

### Table 1: Sensitivity and Specificity of Markers Used to Identify Cardiac Fibroblasts

| Marker          | Sensitivity                                                                 | Specificity                                                                 |
|-----------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Vimentin        | Labels all fibroblasts (180,181).                                            | Also expressed by other cells of mesenchymal origin (endothelial cells [182], vascular smooth muscle cells [183], etc.). |
| α-SMA           | Expressed by activated myofibroblasts in fibrotic hearts (22,41,138). Not expressed by quiescent fibroblasts (137). | Also expressed by vascular mural cells.                                      |
| Col1α1          | Synthesis of structural collagens is a hallmark of fibroblasts in normal and remodeling hearts (42,141). | Although synthesis of structural collagens by cells other than fibroblasts has been reported, expression of Col1α1 in cardiac endothelial cells, immune cells, vascular smooth muscle cells, and pericytes is negligible when compared to fibroblasts (141). Because of labeling of the surrounding matrix, antibodies to collagens may be suboptimal for fibroblast identification. Col1α1-GFP reporter mice represent an excellent tool for identification of fibroblasts in many organs, including the heart (42). |
| Periostin       | Expressed by fibroblasts in neonatal hearts but not by fibroblasts in normal adult hearts (184). Highly expressed in activated cardiac fibroblasts after injury (185,186). | May also be expressed by subsets of vascular smooth muscle cells (187). |
| Fibronectin ED-A | Highly expressed by activated myofibroblasts (188).                         | Deposited in the matrix (189). May also colocalize with macrophages, endothelial cells, and other cell types (190,191). |
| PDGFRα          | Highly expressed in cardiac fibroblasts in normal (41) and pressure-overloaded myocardium (141). | Although vascular smooth muscle cells have been reported to express PDGFRα, especially under conditions of stress (192), PDGFRα-GFP reporter lines seem to predominantly identify cells with fibroblast-like characteristics (193). |
| DDR2            | High expression in cardiac fibroblasts in normal adult hearts (194), colocalizing with vimentin and col1α1 (195). May also be expressed in various subpopulations of infarct fibroblasts and myofibroblasts (196). | DDR2 expression has been reported in activated endothelial cells (197) and in stretched vascular smooth muscle cells (198). It is unclear whether this affects the specificity of DDR2 for fibroblasts in injured and remodeling hearts. |
| Antigen recognized by MEFSK4 | The MEFSK4 antibody labels through flow cytometry almost all PDGFRα+, Col1α1+ cardiac fibroblasts (14). No antibodies are available for immunohistochemistry. | MEFSK4 has been reported to label a small subpopulation of pericytes (14). |
| Cluster of differentiation 90 (Tyfi) | Identifies a subpopulation of fibroblasts in the normal and remodeling myocardium (14,141,199,200). | Also expressed by immune cells, lymphatic endothelial cells, and pericytes (201). |
| Scal            | Identifies a subpopulation (~60%) of PDGFRα+, Col1α1+ fibroblasts in the murine heart (14). | Lacks specificity. In Scal-GFP reporter mice, Scal expression colocalized with endothelial and pericyte markers (202). |
| Tcf21           | Labels the majority of fibroblast-like cells in normal myocardium (19). In infarcted and pressure-overloaded hearts, accumulation of Tcf21+ fibroblast-like cells is noted; however, according to a single report, Tcf21 may not label activated α-SMA+ myofibroblasts (203). | Relatively specific for fibroblast populations. Not expressed by immune cells (CD45+1) (203), endothelial cells, and vascular smooth muscle cells (19). |
| FSP1            | No expression in fibroblasts in the normal adult myocardium. In the infarcted and pressure-overloaded heart, there is a marked expansion of FSP1+ cells. The majority of these cells cannot be identified as α-SMA+ myofibroblasts (141,184). | Lacks specificity. The majority of FSP1+ cells in injured and remodeling hearts are endothelial cells, macrophages, and vascular smooth muscle cells (184,204). |
| FAP             | Not expressed in normal cardiac fibroblasts (174). Labels many activated fibroblasts in infarcted rat hearts and in human myocardial samples from patients with post-infarction heart failure (205). | Specific for activated fibroblasts. However, in human failing hearts, FAP expression has been reported in small populations of inflammatory cells and endothelial cells (205). |

Col1α1 — collagen 1α1; DDR2 — discoidin domain receptor 2; FAP — fibroblast-activation protein; FSP1 — fibroblast-specific protein 1; GFP — green fluorescent protein; PDGFRα — platelet-derived growth factor α; Scal — stem cell antigen-1; SMA — smooth muscle actin; Tcf21 — transcription factor 21.

**Phenotypic Changes and Role of Cardiac Fibroblasts in the Infarcted Myocardium**

Fibroblasts are characterized by their ability to respond to mechanical stress or stimulation with soluble mediators. In vitro, cardiac fibroblasts cultured in the low-tension environment of a collagen-based pad have morphological properties similar to those of fibroblasts in normal myocardium. When subjected to mechanical stress or stimulation with soluble mediators, fibroblasts exhibit remarkable phenotypic plasticity and undergo dramatic alterations in their gene expression profile and functional properties. This response is critical in the repair and remodeling processes that occur in the infarcted myocardium after myocardial infarction.
expression of myofibroblast markers, such as \( \alpha \)-smooth muscle actin (SMA) (22). In contrast, when cultured in plates, fibroblasts undergo conversion to myofibroblasts, exhibiting activation of mechanosensitive signaling pathways that trigger incorporation of \( \alpha \)-SMA into stress fibers and induce synthesis of ECM proteins. In vivo, cardiac fibroblasts respond to changes in their microenvironment by acquiring a wide range of phenotypic profiles, thus serving as inflammatory, matrix-synthetic, or proangiogenic cells depending on the context (Central Illustration).

In myocardial infarction, sudden occlusion of a coronary artery results in the death of up to 1 billion cardiomyocytes, triggering an intense inflammatory reaction (23). Because the massive loss of cardiomyocytes overwhelms the extremely limited regenerative potential of the adult mammalian heart, the infarcted myocardium heals through formation of a scar. Thus, repair of the infarcted heart is dependent on a well-orchestrated cellular response, composed of 3 distinct but overlapping phases. During the inflammatory phase, innate immune activation in response to release of damage-associated molecular patterns by dying cardiomyocytes and degraded ECM triggers cytokine and chemokine induction and recruits leukocytes that clear the infarct from necrotic and apoptotic cells and remove matrix debris (24). Macrophages phagocytosing apoptotic cells undergo transition to an anti-inflammatory phenotype, mediating suppression of inflammation and activation of a reparative program that orchestrates the proliferative phase of cardiac repair, characterized by expansion of myofibroblasts and vascular cells. The maturation phase follows and is associated with quiescence of fibroblasts, recruitment of mural cells by infarct neovessels, and formation of a crosslinked collagenous scar (25). During the 3 phases of infarct healing, cardiac fibroblasts undergo rapid phenotypic transitions from quiescence to a pro-inflammatory and matrix-degrading phenotype to a matrix-synthetic myofibroblast phenotype, only to revert to quiescence as the scar matures. Emerging evidence suggests that fibroblasts do not simply follow the changes in their microenvironment but serve as critical regulators of the cellular events in every phase of cardiac repair (26).

**The Fibroblasts in the Inflammatory Phase of Infarct Healing.** Fibroblasts are capable of producing large amounts of proinflammatory cytokines and chemokines in response to stimulation with reactive oxygen species (ROS), Toll-like receptor ligands, or interleukin (IL)-1\( \beta \) (27-29). During the early post-ischemic phase, interstitial fibroblasts may sense damage-associated molecular patterns released by dying cardiomyocytes, activating a proinflammatory program (Figure 1). Considering that several other cell types, including cardiomyocytes, endothelial cells, immune cells, and vascular mural cells, can also secrete proinflammatory mediators (30), the relative role of resident cardiac fibroblasts as inflammatory cells remains unclear. In vivo studies have suggested that infarct fibroblasts may exhibit activation of the NLRP3 inflammasome (31,32), thus serving as an important source of active IL-1\( \beta \), a critical proinflammatory cytokine in the infarcted myocardium (33). A recent study suggested that fibroblasts may stimulate leukocyte recruitment in the infarcted myocardium by secreting large amounts of granulocyte/macrophage colony-stimulating factor (34). To what extent proinflammatory fibroblasts also contribute other chemokines or cytokines to the infarct environment remains unknown. Cytokine-activated proinflammatory fibroblasts also secrete proteases that play an important role in clearance of the infarct from matrix debris (35). Associative data have suggested that in addition to their role as proinflammatory and matrix-degrading cells, fibroblasts may protect cardiomyocytes from ischemic injury (36). The molecular signals responsible for the prosurvival actions are unclear.

**The Role of Fibroblasts in the Proliferative Phase of Infarct Healing. The potential role of infarct fibroblasts in phagocytosis and suppression of inflammation.** Activation of the post-infarction inflammatory reaction is followed by rapid suppression of proinflammatory gene synthesis and subsequent resolution of the leukocytic infiltrate, marking the transition to the proliferative phase of infarct healing. Phagocytosis of apoptotic cells plays a key role in downmodulation of inflammation, stimulating release of anti-inflammatory signals, such as IL-10 and transforming growth factor (TGF)-\( \beta \). To what extent fibroblasts participate in repression and resolution of post-infarction inflammation remains unknown. A recent study suggested that activated fibroblasts may serve as phagocytes, engulfing apoptotic cells from the infarct zone (37). Considering the abundance of phagocytic macrophages in the healing infarct (38), the relative contribution of fibroblasts in clearance of dead cells is unclear. Whether any phagocytic actions of fibroblasts are accompanied by secretion of IL-10 or TGF-\( \beta \) and by acquisition of an anti-inflammatory phenotype has not been investigated.
In the dynamic environment of the infarcted heart, cardiac fibroblasts expand, undergo phenotypic changes, and are implicated in a wide range of functions. Coronary occlusion causes death of cardiomyocytes in the area of injury. During the inflammatory phase of infarct healing, Damage-Associated Molecular Patterns (DAMPs) released by dying cells activate a pro-inflammatory phenotype in cardiac fibroblasts that secrete cytokines (such as IL-1, TNF-α, and GM-CSF), and chemokines (such as CCL2) contributing to recruitment and activation of leukocytes. Cytokine-stimulated fibroblasts also secrete matrix metalloproteinases (MMPs), promoting extracellular matrix degradation and release of pro-inflammatory matrix fragments. Some studies have suggested that infarct fibroblasts may also function as phagocytic cells; however, considering the abundance of macrophages in the healing infarct the relative contribution of "phagocytic fibroblasts" remains unclear.

Clearance of the infarcted heart from dead cells stimulates anti-inflammatory signals, leading to suppression of inflammation and transition to the proliferative phase of infarct healing. Fibroblasts expand, predominantly through recruitment of resident populations and undergo myofibroblast conversion, incorporating α-SMA into cytoskeletal stress fibers. Activated myofibroblasts are the main matrix-synthetic cells in the infarcted heart and produce both structural extracellular matrix proteins and matricellular macromolecules. In addition to their contribution in matrix production, fibroblast populations may also contribute to regulation of the angiogenic response and may regulate macrophage phenotype. During scar maturation fibroblasts exhibit disassembly of α-SMA-decorated stress fibers, and may produce matrix-crosslinking enzymes such as lysyl-oxidases (LOX). Reduction of fibroblast numbers in mature scars has been suggested to involve activation of apoptosis. The molecular basis for the phenotypic transitions of cardiac fibroblasts in the phases of infarct healing remains poorly understood. The functional diversity of fibroblasts in the infarcted heart may reflect sequential activation of distinct fibroblast subpopulations, or may result from coordinated responses of the fibroblasts to the dynamic changes in their microenvironment.
During the inflammatory phase of infarct healing, cardiac fibroblasts secrete proinflammatory mediators and matrix-degrading proteases. Damage-associated molecular patterns (DAMPs) released by necrotic cells and matrix fragments activate Toll-like receptor signaling in cardiac fibroblasts. Proinflammatory cytokines (such as interleukin [IL]-1β and tumor necrosis factor [TNF]-α released by endothelial cells, immune cells, and cardiomyocytes and activation of reactive oxygen species (ROS) accentuate fibroblast inflammatory activity. IL-1/IL-1RI signaling has been suggested to reduce α-smooth muscle actin (α-SMA) expression, preventing myofibroblast conversion. Cytokines and chemokines (such as IL-1β, TNF-α, IL-6, and granulocyte/macrophage colony-stimulating factor [GM-CSF]) secreted by activated fibroblasts may contribute to the recruitment of leukocytes, whereas protease release may promote matrix degradation. Considering that several other cell types are capable of secreting inflammatory mediators, the relative contribution of fibroblasts is unclear. The cartoon was designed using Servier Medical Art (https://smart.servier.com). DNA = deoxyribonucleic acid; HMGB1 = high-mobility group protein B1; MMP = matrix metalloproteinase; TNFR = tumor necrosis factor receptor.
Expansion of activated fibroblasts in the infarcted myocardium. Expansion of cardiac fibroblasts and acquisition of a matrix-synthetic myofibroblast phenotype are prominent features of the proliferative phase of infarct healing. In addition to the abundant resident cardiac fibroblasts that can respond to activating signals, several other cell types have been proposed as important cellular sources for the expanding infarct myofibroblast population. Endothelial cells can undergo endothelial-to-mesenchymal transition in response to growth factor stimulation, acquiring a matrix-synthetic phenotype. Hematopoietic fibroblast progenitors can also contribute to the expansion of activated fibroblasts in injury sites. Pericytes and vascular smooth muscle cells can undergo fibroblast conversion, contributing to fibrotic responses. Over the past 10 years, studies combining bone marrow transplantation experiments, parabiosis, and lineage tracing strategies have attempted to explore the cellular origin of fibroblasts in the infarcted heart (Table 2). Although earlier investigations had suggested important contributions of endothelial cells and hematopoietic progenitors to the infarct myofibroblast population (39,40), recent studies using lineage-tracing approaches with several different Cre drivers demonstrated that resident cardiac fibroblasts are the main source for activated myofibroblasts in the infarcted heart, with much smaller contributions of endothelial and hematopoietic cells (41,42). It should be emphasized that the studies investigating the origin of infarct myofibroblasts have several limitations that may explain, at least in part, conflicting findings (43). First, the use of nonspecific fibroblast markers or Cre drivers with questionable specificity may limit the reliability of the findings. For example, some of the studies suggesting major contributions of endothelial cells to the myofibroblast population

### Table 2: Cellular Origin of Fibroblasts in Myocardial Infarction

| Reference # | Main Conclusions of the Study | Strategies Used to Study the Cellular Origin of Infarct Fibroblasts | Markers Used for Fibroblast Identification |
|-------------|--------------------------------|-------------------------------------------------|-------------------------------------------|
| (41)        | Activated fibroblasts in infarcted and remodeling hearts are derived from Tcf21⁺ tissue-resident fibroblasts. Endothelial cells, myeloid cells, and smooth muscle cells do not significantly contribute to the activated fibroblast population. | Lineage-tracing analysis using Cre drivers to study the fate of resident cardiac fibroblasts (Tcf21MCM), activated myofibroblasts (PosdBCre), myeloid cells (Ly6Chs), and vascular smooth muscle cells (MynIlCreERT2). | Vimentin, PDGFRα, α-SMA, FSP1 |
| (137)       | Resident Tcf21⁺ cardiac fibroblasts become activated and proliferative within 2–4 days after nonreperfused infarction, then undergo myofibroblast conversion, secreting large amounts of ECM proteins. Finally in mature scars, fibroblasts show reduced expression of α-SMA and express tendon genes. | The fate of fibroblasts was studied using 3 different lineage-tracing models: Tcf21MCM (resident cardiac fibroblasts), PosdBCre (activated fibroblasts), and Acta2CreERT2 (activated myofibroblasts). | Vimentin, α-SMA |
| (206)       | Epicardial-derived resident mesenchymal cells, not bone marrow cells, are the main source of fibroblasts in the infarcted heart. WTICre mice were used for permanent genetic tracing of epicardium-derived cells. Mice reconstituted with GFP⁺ bone marrow cells were used to study bone marrow origin. | Collagen I, FSP1, DDR2, CD90, α-SMA |
| (207)       | Following nonreperfused infarction, subsets of epicardium-derived cells differentiate into fibroblasts and smooth muscle cells. | Lineage tracing of epicardium derived cells by using inducible WTICreERT2 mice. | FSP1, procollagen I, collagen III, fibronectin, α-SMA |
| (42)        | The vast majority of activated collagen-producing fibroblasts (~96%) in nonreperfused infarcts are derived from epicardial cells. Hematopoietic, bone marrow lineages, and endothelial cells do not significantly contribute to the fibroblast population. | Lineage-tracing models to label epicardial cells (WTICre), endothelial cells (Tie2Cre), hematopoietic cells (VavCre). Transplantation with GFP⁺ bone marrow to study bone marrow origin. | Breeding with collagen 1×1-GFP reporter mice, α-SMA |
| (39)        | Post-infarction, 35%–40% of α-SMA⁺ mesenchymal cells are derived from endothelial cells, possibly through endothelial-to-mesenchymal transition. | The endothelial cell-specific endothelial-SCLCreERT mouse line was used to track endothelial cells. | α-SMA expression, Snail, FSP1, vimentin and collagen I mRNA expression |
| (208)       | 24% of myofibroblasts in nonreperfused myocardial infarcts originate from bone marrow cells. | Transplantation with EGFP-tagged bone marrow, or bone marrow from proCol1α2 gene-driven luciferase or β-Gal reporter mice. | α-SMA staining, β-galactosidase activity in pro-Col1α2-driven chimeric mice |
| (40)        | 25% of vimentin⁺ fibroblasts and 57% of α-SMA⁺ myofibroblasts in nonreperfused infarcts are derived from bone marrow cells. | Transplantation with bone marrow from EGFP reporter mice to document bone marrow origin. | α-SMA, vimentin |
| (209)       | Blood-derived cells contributed to the myofibroblast population. Treatment with G-CSF enhances recruitment of bone marrow-derived myofibroblasts. | Transplantation of GFP⁺ bone marrow. | Vimentin, α-SMA |
| (210)       | Gli-1⁺ perivascular cells contribute to the myofibroblast population in the infarcted myocardium (approximately 60% of activated myofibroblasts are derived from Gli-1⁺ cells). | Lineage tracing using GliCreERT2 mice. | Collagen I, PDGFRα, α-SMA |

ECM = extracellular matrix; EGFP = enhanced green fluorescent protein; G-CSF = granulocyte-colony stimulating factor; mRNA = messenger ribonucleic acid; other abbreviations as in Table 1.
During the proliferative phase of infarct healing, fibrogenic growth factors and neurohumoral mediators trigger myofibroblast conversion and stimulate fibroblast proliferation, migration, and activation. A wide range of fibrogenic mediators, induced during the proliferative phase of cardiac repair, are implicated in myofibroblast activation. Neurohumoral mediators, such as angiotensin II (AngII), aldosterone, and norepinephrine (NE), growth factors (transforming growth factor [TGF]-βs, fibroblast growth factors [FGFs], platelet-derived growth factors [PDGFs]), and specialized matrix proteins, such as ED-A fibronectin and matricellular proteins cooperate to activate intracellular signaling pathways that promote myofibroblast conversion and proliferation and modulate expression of extracellular matrix (ECM) proteins and of genes associated with matrix metabolism. The cartoon was designed using Servier Medical Art (https://smart.servier.com). AR = adrenergic receptor; ET = endothelin; MMP = matrix metalloproteinase; NF = nuclear factor; ROS = reactive oxygen species; SMA = smooth muscle actin; TIMP = tissue inhibitor of metalloproteinase.
were based on nonspecific Cre drivers (such as the Tie1-Cre line) (44). Identification of fibroblasts represents another major challenge due to the absence of specific markers (Table 1). Thus, in many cases, conclusions regarding conversion of other lineages into fibroblasts are based on immunofluorescence data showing expression of nonspecific markers, such as fibroblast-specific protein-1 or α-SMA (40,44).

Second, the timing of reperfusion may have dramatic effects on the fate of resident myocardial cells and on recruitment of blood-derived progenitors, thus altering the relative contribution of various cell types to the expansion and activation of fibroblasts. Early reperfusion results in accentuated and accelerated leukocyte influx and could also augment infiltration of the infarct zone with bone marrow-derived fibroblast progenitors. Prolonged coronary occlusion, in contrast, may cause ischemic death of large numbers of interstitial and vascular cells in the infarct zone, thus reducing their relative contribution to myofibroblast expansion.

Third, considering that all lineage-tracing studies were performed in mouse models, there is practically no information on the origin of myofibroblasts in human myocardial infarction. Myofibroblast migration in the border zone of the infarct. In the healing infarct, fibroblasts undergo conversion to myofibroblasts, expressing contractile proteins, such as α-SMA and the embryonic isoform of smooth muscle myosin heavy chain, synthesizing periostin, and secreting large amounts of ECM proteins (22,45). In animal models of myocardial infarction, myofibroblasts are localized predominantly in the border zone, forming well-organized arrays (46). Fibroblast migration to the infarct border zone may be mediated by growth factors, such as TGF-β and fibroblast growth factors (FGFs) (47,48), and by proinflammatory cytokines, such as IL-1β, tumor necrosis factor-α, and cardiotoxin-1 (27,49). It has also been suggested that chemokines, such as monocyte chemoattractant protein-1/C-C motif chemokine ligand 2, may promote the migration of bone marrow-derived fibroblast progenitors in injured tissues. Considering the robust evidence documenting no significant contribution of hematopoietic cells on infarct fibroblast populations (42), the potential significance of this mechanism is unclear. C-C motif chemokine ligand 2 may contribute to fibrosis through recruitment and activation of fibrogenic monocytes and macrophages (50,51) rather than through recruitment of circulating fibroblast progenitors or modulation of fibroblast function. A recently published investigation identified a subpopulation of atypical monocytes with a critical contribution in bleomycin-induced pulmonary fibrosis (52). Whether fibrogenic monocyte subsets with distinct phenotypic profiles are recruited in remodeling hearts has not been investigated. Other members of the chemokine family, such as the CXC chemokine interferon-γ-inducible protein-10/CXCL10, may inhibit fibroblast migration, serving as an endogenous inhibitory signal that restrains the fibrotic response following injury (53,54).

Fibroblast migration is dependent on the continuous formation and disruption of adhesive interactions between fibroblast surface proteins and the surrounding cardiac ECM. Migration involves well-orchestrated activation of integrins on cardiac fibroblast cytoplasmic membrane (55), linked with the production of proteases that degrade the matrix (56) and expression of specialized matrix proteins that locally activate or transduce growth factor-mediated signals (57).

The effects of neurohumoral pathways on activation of infarct myofibroblasts. After migrating to the infarct border zone, fibroblasts acquire a proliferative matrix-synthetic phenotype through the local induction of fibrogenic mediators (Figure 2). Neurohumoral pathways are critically implicated in regulation of fibroblast function following myocardial infarction. Potent activation of the renin-angiotensin-aldosterone system in infarcted hearts (58) stimulates myofibroblast conversion, proliferation, and ECM protein synthesis both through direct actions, and via induction of TGF-β (59,60). The fibrogenic actions of angiotensin II are mediated predominantly through engagement of the angiotensin type 1 (AT1) receptor (61–64). In contrast, the AT2 receptor may exert inhibitory functions, suppressing fibroblast proliferation and ECM synthesis (65), and has been suggested to restrain profibrotic signaling (66). Although extensive in vivo evidence supports the profibrotic actions of AT1 signaling in experimental models of myocardial infarction (67), to what extent the prosurvival effects of angiotensin-converting enzyme inhibition and AT1 blockade in patients with acute myocardial infarction are mediated through attenuation of angiotensin-induced fibrosis remains unknown.

Both animal model studies and investigations in human patients suggest that aldosterone contributes to myocardial fibrosis (68). Mineralocorticoid receptor inhibition attenuated fibrosis in experimental models of nonreperfused myocardial infarction (69) and reduced levels of biomarkers reflecting collagen synthesis in patients with acute myocardial infarction (70). The cellular basis for these effects remains unclear. Aldosterone-mediated signaling has been
suggested to modulate the phenotype of all cells involved in cardiac repair, driving macrophages toward a fibrogenic phenotype (71), activating T cells (72), inducing cardiomyocyte-derived fibrogenic signals (73), and directly stimulating fibroblast proliferation and collagen synthesis (74,75).

The adrenergic system is also prominently activated following myocardial infarction. Stimulation of β2-adrenergic receptor signaling directly stimulates proliferation of cardiac fibroblasts through effects that may involve p38 mitogen-activated protein kinase (MAPK) signaling (76-78). Chronic pharmacological stimulation or transgenic overexpression of β-adrenergic receptor causes myocardial fibrosis (79); whether fibrotic remodeling is due to direct activation of fibroblasts or reflects reparative fibrosis in response to cardiomyocyte death remains unknown. Activation of G protein-coupled receptor kinase 2 in cardiac fibroblasts may transduce, at least in part, the fibrogenic actions of β-adrenergic receptors in the infarcted myocardium (80,81).

The role of TGF-β3 in fibroblast activation. The fibrogenic growth factor TGF-β is a central mediator in myofibroblast conversion following myocardial infarction. All 3 TGF-β isoforms are markedly up-regulated in the infarcted heart; TGF-β1 and TGF-β2 are induced earlier, whereas TGF-β3 exhibits a late peak and a prolonged time course of expression (82). Whether TGF-β isoforms play distinct roles following infarction remains unknown. Most myocardial cell types are capable of secreting TGF-β as an inactive complex bound to the latency-associated peptide (forming the small latent complex), and latent TGF-β-binding protein (forming the large latent complex). Several mediators, including ROS, cell surface integrins, proteases, and matricellular proteins (such as thrombospondin-1), have been implicated in generation of active TGF-β in the healing heart (83-87). The active TGF-β dimer binds and sequentially transphosphorylates type II and type I TGF-β receptors, activating downstream canonical signaling pathways through receptor-activated Smad proteins (R-Smads-Smad2/3) and Smad-independent pathways (88). Both Smad-dependent and non-Smad pathways have been implicated in α-SMA and ECM protein up-regulation, triggering myofibroblast conversion and activation in healing myocardial infarction (89). In the infarcted heart, activation of Smad3-dependent signaling in cardiac fibroblasts plays a crucial role in formation of well-organized fibroblast arrays in the infarct border zone by inducing integrin expression (90).

Endothelin-1. The endothelium-derived peptide endothelin-1 is a potent vasoconstrictor but has also been reported to exert fibroblast-activating effects. Endothelin-1 secreted by TGF-β- or angiotensin II-stimulated endothelial cells may stimulate fibroblast proliferation, myofibroblast conversion, and ECM synthesis through activation of the endothelin-A receptor and downstream Rac/Pi3K/Akt signaling pathways (91). In vivo, cardiac-specific endothelin-1 overexpression caused myocardial fibrosis associated with biventricular systolic and diastolic dysfunction (92), whereas endothelin antagonism attenuated adverse fibrotic remodeling following myocardial infarction (93).

The role of FGFs and platelet-derived growth factors in the activation of infarct fibroblasts. FGF2 may stimulate a proliferative phenotype in infarct fibroblasts through activation of p38 MAPK and protein kinase Cδ signaling pathways (94). In vivo, FGF2-knockout mice had reduced proliferation of infarct fibroblasts, associated with decreased ECM synthesis. These defects resulted in impaired scar formation and infarct expansion. In contrast, FGF2 overexpression increased fibroblast proliferation and accentuated ECM deposition (95). PDGFs and PDGF receptors (PDGFRs) are also overexpressed in the infarcted myocardium and may play a role in regulation of fibroblast function (96). Activation of PDGFβR signaling may promote fibroblast activation; in contrast, PDGFβR actions are important for maturation of the infarct vasculature. In vitro, PDGF-AA potently stimulates cardiac fibroblast proliferation and ECM protein synthesis (97). In vivo, PDGFβR and PDGFβR neutralization reduced collagen deposition in reperfused myocardial infarcts (96); however, PDGFβR inhibition also prevented the recruitment of mural cells by infarct neovessels, perturbing maturation of the infarct vasculature (96).

The role of specialized ECM proteins in the regulation of infarct fibroblast phenotype. Tissue injury is associated with induction of specialized matricellular proteins that do not play a primary structural role but regulate cellular responses by transducing or modulating signaling cascades. Fibroblasts are important cellular targets of specialized ECM proteins. The ED-A domain of fibronectin plays a crucial role in conversion of fibroblasts into myofibroblasts (98-100). Moreover, several matricellular macromolecules, including thrombospondins (87), osteopontin (101), tenascin-C (102), secreted protein acidic and rich in cysteine (103), peristin (104), and osteoglycin (105), have been implicated in activation of myofibroblasts in healing infarcts. Non-fibrillar collagens, such as collagen VI, are also involved in the activation of a myofibroblast phenotype following myocardial infarction (106). Most
specialized matrix proteins act by binding to fibroblast surface molecules, such as integrins and syndecans, or by modulating activity of growth factors and proteases.

**Intracellular molecular pathways involved in fibroblast activation.** In the healing infarct, induction of fibrogenic stimuli, such as damage-associated molecular patterns, cytokines and growth factors, neurohumoral mediators, and matricellular proteins cooperate to stimulate intracellular cascades involved in myofibroblast conversion, migration, proliferation, and induction of a matrix-synthetic transcriptional program (107). Experimental studies have identified several essential intracellular pathways that contribute to fibroblast activation.

The ROS system acts as a common effector of many fibrogenic signals (108). Angiotensin II activates downstream ROS-sensitive kinases (109) and stimulates collagen synthesis through ROS generation (110). Aldosterone-induced fibroblast activation is mediated, at least in part, through oxidative stress (111). Moreover, extensive evidence suggests that ROS mediate the fibrogenic actions of TGF-β and critically regulate matrix metabolism by modulating synthesis and activity of proteases involved in ECM degradation (112).

Ca²⁺ oscillations have also been implicated in the regulation of fibroblast phenotype and function (113). Angiotensin II or TGF-β may induce fibrogenic actions, at least in part through activation of members of the transient receptor potential (TRP) family of cationic channels. In cardiac fibroblasts, the calcium channel TRPC6 has been implicated in myofibroblast conversion by activating a calcineurin-nuclear factor of activated T cells cascade (114,115).

MAPKs exhibit a broad range of functions in many different cellular responses, including cell proliferation, survival, migration, and differentiation. Both in vitro and in vivo studies suggest an important role for MAPK signaling pathways in fibroblast activation. Fibroblast-specific loss-of-function approaches suggested that activation of p38 MAPK, the major isoform expressed in cardiac fibroblasts (116), promotes myofibroblast conversion following infarction through activation of the transcription factor serum response factor and the signaling effector calcineurin (78,117). The serum response factor/myocardin-related transcription factor (MRTF) axis plays a dominant role in regulation of α-SMA transcription and subsequent myofibroblast conversion (118,119). In vivo, mice with global loss of MRTF-A had attenuated fibrosis following myocardial infarction (120). Whether these observations reflect abrogation of MRTF-dependent effects on fibroblasts remains unclear, considering that MRTF-A may also modulate cardiomyocyte and vascular cell phenotype and function (121,122).

**Noncoding ribonucleic acids in regulation of infarct fibroblasts.** A growing body of evidence demonstrates that noncoding ribonucleic acids (RNAs), including small noncoding microRNA (miRNAs) and long noncoding RNA (IncRNA), may be implicated in the regulation of fibroblast activity in the infarcted heart (123,124). MiRNAs may act by modulating several profibrotic target pathways, including the TGF-β/Smad system, angiotensin II/MAPK signaling, the RhoA/Rho-associated coiled-coil containing kinase (ROCK) cascade, the MRTF/serum response factor axis, and the cationic channels regulating calcium responses (125). Several miRNAs, such as miR-29 and miR-101, function as negative regulators of cardiac fibroblasts; repression of these miRNAs by fibrogenic stimuli, such as TGF-β, may activate a fibrogenic program in response to infarction (126,127). Members of the miR-15 family have also been suggested to exert antifibrotic actions by inhibiting the TGF-β pathway (128). In contrast to other antifibrotic miRNAs, miR-15 is up-regulated following cardiac injury and may play a role in restraining the fibrotic response.

Other miRNAs may function as activators of the fibrogenic cascade, promoting myofibroblast conversion and activation in the infarcted heart. MiR-21 is markedly induced in infarct fibroblasts (129) and may exert fibrogenic actions by stimulating MAPK activation in cardiac fibroblasts (130) or by targeting the TGF-β cascade (131). In addition to its effects on the fibrotic response, fibroblast-derived miR-21, packaged into exosomes, may exert paracrine effects on cardiomyocyte hypertrophy and immune cell activation (132).

Evidence on the role on IncRNAs in fibroblast activation following infarction is limited (133). Wisp2 superenhancer-associated RNA, a cardiac fibroblast-enriched IncRNA, has been implicated in fibroblast proliferation, activation, and survival following myocardial infarction (134). The species specificity of IncRNAs (only 15% of mouse IncRNAs are expressed in humans and vice versa) is a major limiting factor in the use of animal models to understand their role in human diseases (135).

**FIBROBLASTS IN SCAR MATURATION.** In healing infarcts, secretion of structural ECM proteins by activated myofibroblasts is followed by induction of matrix crosslinking enzymes that contribute to scar maturation. As the scar matures, the density of activated myofibroblasts is dramatically reduced (45).
Depletion of myofibroblasts from the mature scar may reflect apoptosis of fibroblasts (136) or loss of α-SMA expression and acquisition of a distinct fibroblast phenotype, characterized by high expression of tendon genes (137). The molecular signals responsible for apoptosis, or deactivation of scar myofibroblasts remain unknown.

CHRONIC ACTIVATION OF FIBROBLASTS IN THE REMODELING NONINFARCTED MYOCARDIUM. As the infarcted heart heals, the surviving myocardium exhibits chronic remodeling, associated with cardiomyocyte hypertrophy and interstitial fibrotic changes. Increased wall stress in noninfarcted myocardial segments may activate interstitial fibroblasts, promoting a matrix-synthetic phenotype and contributing to segmental dysfunction. Although chronic fibrotic changes have been reported in remodeling noninfarcted segments, and some studies have suggested persistence of myofibroblasts for many years in patients surviving an acute infarction (138), the relative contribution of chronic fibroblast activation in the pathogenesis of post-infarction heart failure remains unknown.

THE FIBROBLASTS IN THE PRESSURE-OVERLOADED MYOCARDIUM

Increased afterload is a common pathophysiologic companion of many cardiac pathologic conditions, including hypertensive heart disease and aortic stenosis. A pressure load imposes mechanical stress on all myocardial cells and triggers a series of molecular events leading to hypertrophic and fibrotic ventricular remodeling and ultimately heart failure (139). Expansion of resident cardiac fibroblast populations is a prominent characteristic of cardiac pressure overload (140,141) and is associated with activation of a matrix-synthetic program and subsequent deposition of collagens in interstitial and perivascular areas. Neurohumoral activation has been critically implicated in pressure overload–induced cardiac fibrosis. Angiotensin II-mediated AT1 activation mediates interstitial fibrosis in models of left ventricular pressure overload (142), through direct actions and via induction of inflammatory cytokines and growth factors. Although fibrogenic actions of proinflammatory cytokines, such as tumor necrosis...
factor-α and IL-6, have been reported in pressure-overload models, whether these effects involve direct modulation of fibroblast phenotype or reflect indirect actions on macrophages or cardiomyocytes remains unknown (143,144). Moreover, TGF-β-driven activation of Smad-dependent signaling has been implicated in fibroblast activation in the pressure-overloaded heart (145).

Considering that mechanical stress is the primary insult in the pressure-overloaded myocardium, activation of mechanosensitive signaling pathways in cardiac fibroblasts may be the critical initial event involved in the pathogenesis of interstitial fibrosis. The focal adhesion-integrin complex is a primary mechanosensor in fibroblasts and transduces molecular signals that promote ECM gene transcription and myofibroblast conversion (146). Focal adhesion kinase (FAK) is a critical molecular link between mechanical stress and fibroblast activation. In vitro, FAK activation has been demonstrated to mediate mechanosensitive or growth factor-induced myofibroblast conversion (147-149). In vivo, FAK knockdown attenuated fibrotic changes in a model of cardiac pressure overload (150). However, considering the broad effects of FAK activation on cardiomyocytes and vascular and interstitial cells, the cellular basis for these effects is unclear. Evidence documenting the role of fibroblast-specific FAK activation in cardiac fibrosis is lacking.

Mechanosensitive ion channels have also been implicated in pressure overload-induced fibroblast activation (146). TRPC3 and TRPV4 have been implicated in myofibroblast conversion in response to mechanical stress or to growth factor stimulation (151,152). A recent study demonstrated a critical role for fibroblast-specific activation of the TWIK-related potassium channel in the activation of a fibrogenic response in the pressure-overloaded myocardium (153).

Mechanosensitive or neurohumoral activation of the small GTP-binding protein RhoA may also play an important role in fibroblast proliferation and activation following pressure overload, signaling through the ROCKs, ROCK1 and ROCK2 (154,155). In an experimental model of cardiac pressure overload, pharmacological inhibition of the RhoA-ROCK pathway attenuated fibrosis (156). Fibroblast-specific ROCK2 signaling has been suggested to mediate angiotsin II-mediated fibrosis, through induction of FGF2 and of the matricellular protein CCN2 (157). In addition to the direct fibrogenic actions of mechanosensitive signaling pathways, pressure overload may activate fibroblasts indirectly, through mechanical stress-induced actions on cardiomyocytes, T lymphocytes, or macrophages (158,159).

It should be emphasized that the contribution of fibroblasts in the pressure-overloaded myocardium is not limited to synthesis of ECM proteins and subsequent increase in ventricular stiffness. Activated fibroblasts may function as potent modulators of cardiomyocyte prosurvival and hypertrophic responses by secreting growth factors or through the release of miRNA-containing exosomes (160,161). Recent work suggested that TGF-β/Smad-dependent matrix-preserving actions of activated myofibroblasts prevent the generation of proinflammatory ECM fragments and play a critical role in protection of the pressure-overloaded myocardium from inflammation and systolic dysfunction (162). Thus, activated fibroblasts in the pressure-overloaded heart are not unidimensional cells that mediate fibrosis and dysfunction but may also exert protective actions preventing myocardial injury (Figure 3). Whether the diverse actions of fibroblasts in the remodeling myocardium are mediated through distinct fibroblast subpopulations remains unknown.

**FIBROBLASTS IN THE VOLUME-OVERLOADED HEART**

Conditions associated with volume overload, such as severe aortic or mitral valve regurgitation, are associated with marked ventricular dilation and progressive systolic dysfunction. Studies in experimental models of chordal rupture-induced mitral regurgitation in the dog (163,164) and of aortocaval fistula in the rat (165,166) suggest that volume overload causes unique interstitial perturbations that may contribute to adverse remodeling. In contrast to the marked increase in collagen deposition noted in pressure-overloaded hearts, the volume-overloaded myocardium exhibits a marked loss of interstitial collagen associated with increased MMP expression (163,164), reduced collagen synthesis (167), and accentuated collagen degradation (166,168). The matrix-degrading phenotype of interstitial cells in volume-overloaded hearts has been attributed to release of cardiomyocyte-derived TNF-α (165) or to down-modulation of TGF-β signaling (163). Whether these changes reflect perturbations of fibroblast phenotype and function in response to volume overload-induced stretch remains unknown.

**FIBROBLAST ACTIVATION IN THE AGING AND DIABETIC HEART**

Aging, diabetes, obesity, and metabolic dysfunction are associated with progressive interstitial and perivascular fibrosis that may contribute to the
pathogenesis of heart failure with preserved ejection fraction (5,169–173). In contrast to the rapid accumulation of α-SMA-expressing myofibroblasts in models of acute cardiac injury, diabetes and aging do not typically trigger myofibroblast conversion but may cause induction of a matrix-preserving program in cardiac interstitial cells (174). The cellular events and molecular mechanisms mediating fibrosis in senescent and diabetic hearts remain poorly understood. In aging hearts, fibroblast activation may involve the cooperation of several distinct pathways, including age-associated induction of the ROS system, activation of neurohumoral mediators, and stimulation of cytokine and TGF-β-mediated responses (175). In diabetic subjects, in contrast, hyperglycemia may result in accumulation of advanced glycation end-products that crosslink the cardiac ECM, while directly activating fibroblasts by triggering receptor for advanced glycation end-product-mediated signals (176) and accentuating age-associated changes. Diabetes-associated induction of matrilinear proteins, such as thrombospondin-1, may also promote fibrosis by activating growth factor-dependent signaling in cardiac fibroblasts (177). Fibroblast activation in diabetic hearts may also reflect microvascular inflammation or resident macrophage stimulation and subsequent secretion of fibrogenic signals (5,178). It should be emphasized that although aging is associated with increased basal interstitial and perivascular collagen deposition, senescent animals exhibit perturbed fibroblast responses following injury, associated with blunted activation of growth factor signaling pathways (179).

CONCLUSIONS AND FUTURE DIRECTIONS

Expansion and activation of resident fibroblast populations play an important role in repair and remodeling of the injured heart and are implicated in the pathogenesis of systolic and diastolic dysfunction in chronic heart failure. Emerging evidence suggests that activated fibroblasts are not unidimensional matrix-producing cells but exhibit a wide range of phenotypes and may regulate inflammatory, hypertrophic, and prosurvival responses. Several important questions remain to be answered. Does the diversity of functional effects of cardiac fibroblasts in the remodeling heart reflect actions of distinct fibroblast subpopulations? If so, what are the phenotypic characteristics, origin, and fate of these fibroblast subsets? Does the functional pluralism of fibroblasts reflect their high responsiveness to changes in their microenvironment? Which molecular signals and environmental cues drive the dramatic phenotypic changes of cardiac fibroblasts in remodeling hearts? Do cell biological processes documented in mouse models recapitulate the phenotypic changes of fibroblasts in human hearts? Answering these questions is critical in order to design novel therapeutic approaches for patients with heart failure.

ADDRESS FOR CORRESPONDENCE: Dr. Nikolaos G. Frangogiannis, The Wilf Family Cardiovascular Research Institute, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Forchheimer G46B, Bronx, New York 10461. E-mail: nikolaos.frangogiannis@einstein.yu.edu.

REFERENCES

1. Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med 2019;65:70–99.
2. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007;117:568–75.
3. Kong P, Christia P, Frangogiannis NG. The pathogenesis of cardiac fibrosis. Cell Mol Life Sci 2014;71:549–74.
4. Aoki T, Fukushima Y, Sugimura K, et al. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J 2011;75:2605–13.
5. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263–71.
6. Kato S, Saito N, Kirigaya H, et al. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 2015;191:314–9.
7. Roy C, Slimani A, de Meester C, et al. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson 2018;20:55.
8. Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 2014;35:657–64.
9. Ivey MJ, Tallquist MD. Defining the cardiac fibroblast. Circ J 2016;80:2269–76.
10. Phipps RP, Borrello MA, Blieden TM. Fibroblast heterogeneity in the periodontium and other tissues. J Periodontol 1997;32:159–65.
11. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009;105:1164–76.
12. Zaki R. Development and proliferative capacity of cardiac muscle cells. Circ Res 1974;35 Suppl II:17–26.
13. Banerjee I, Fuserle JW, Price RI, Borg TK, Baudino TA. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007;293:H1883–91.
14. Pinto AR, Rynsky A, Ivey MJ, et al. Revisiting cardiac cellular composition. Circ Res 2016;118:400–9.
IL-1β synthesis, secretion, and degradation. In Kawaguchi M, Takahashi M, Hata T, et al. Release preformed TNF-alpha, initiating the cyto-
30. lia. Cell Tissue Res 2016;365:591-309.

Inflammation to myocardial infarction:” further evidence of a signi-
54. ficant adaptive response following myocardial infarction. J Clin Invest 2017;127:383-401.
65. Ohashi O, Yotsumoto Y, Arita A, et al. NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-
67. reperfusion injury. Cardiovasc Res 2013;99:164-74.
60. Bajaksouzian S, Dobaczewski M, Chatila K, et al. Interleukin-1 receptor type 1 signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 2008;173:57-67.
54. Andzi A, Choi JL, He S, et al. The infected myocardium solicits GM-CSF for the detrimental oversupply of inflammatory leukocytes. J Exp Med 2017;214:3293-330.
50. Saxena A, Chen W, Su Y, et al. IL-1β induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol 2013;191:4838-48.
49. Abrial M, Da Silva CC, Pilotto B, et al. Cardiac fibroblasts protect cardiomyocytes against lethal ischemia-reperfusion injury. J Mol Cell Cardiol 2014;68:56-65.
47. Nakaya M, Watari K, Tajima M, et al. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction. J Clin Invest 2017;127:383-401.
46. DeBerge M, Yeap YY, Dehn S, et al. MerTK cleavage on resident cardiac macrophages compromises repair after myocardial ischemia reper-
fusion injury. Circ Res 2017;121:930-40.
45. Asagbonhi O, Rai M, Ryzhov S, Atria N, Feoktistov I, Hatzopoulos AK. Experimental myocardial infarction triggers canonical Wnt signaling and endothelial-to-mesenchymal transi-
50. tion. Dis Model Mech 2011;4:469-83.
44. Mollmann H, Nef HM, Kostin S, et al. Bone marrow-derived mesenchymal stromal cells differentiate into cardiac progenitors in vivo. Cardiovasc Res 2014;103:217-27.
43. Manso AM, Kang SM, Ross RS. Integrins, focal adhesions, and cardiac fibroblasts. J Investig Med 2009;57:856-60.
40. Gherzi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptide complex. J Biol Chem 2002;277:29231-41.
39. Murphy-Ullrich JE. The de-adhesive activity of CCL2/monocyte chemotactrant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881-9.
36. Frangiogianis NG, Dewald O, Xie Y, et al. Critical role of monocyte chemotactrant protein-1/CCL2 chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007;115:584-92.
33. Ieda M, Takahashi T, Ivey KN, et al. Cardiac fibroblasts and myocytes: further evidence of a signi-
54. ficant adaptive response following myocardial infarction. J Clin Invest 2001;107:785-90.
32. Weber KT, Sun Y, Bhattacharya SK, Alhokas RA, Geiling IC. Myofibroblast-mediated mechanisms of pathological remodeling of the heart. Nat Rev Cardiol 2012;10:15-26.
29. Kaygusuz S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
26. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-betal in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997;29:1947-58.
25. Schorb W, Booz GW, Dostal DE, Conrad KM, Chung KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993;72:1245-54.
Fibroblasts in Infarcted and Failing Hearts

62. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23.

63. Crabos M, Roth M, Hahn AW, Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 1994;93:2372-8.

64. Thibault G, Lacombe MJ, Schnapp LM, Lacasse A, Bouzehouane F, Lapalme G. Upregulation of alpha(/beta)1-integrin in cardiac fibroblast by angiotensin II and transforming growth factor-beta1. Am J Physiol Cell Physiol 2000;281: C1467-77.

65. Ohioku N, Matsubara H, Nozawa Y, et al. Angiotensin type II receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997;96:3954-62.

66. Kurisu S, Otsu R, Oshima T, et al. Cardiac angiotensin II type 2 receptor activates the kinin NO system and inhibits fibrosis. Hypertension 2003;41:99-107.

67. Schieffer B, Wigger A, Meibrunn M, et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;90:2273-82.

68. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2009;46:205-12.

69. van den Borne SW, Isobe S, Zanderberg HR, et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. J Am Coll Cardiol Img 2009;2:187-93.

70. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107: 2559-65.

71. Richard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009;54:537-43.

72. Li C, Sun XN, Zeng MR, et al. Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation. Hypertension 2017;70:137-47.

73. Ricard AJ, Morgan J, Bienvenu LA, et al. Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone/salt-mediated inflammation and cardiac fibrosis. Hypertension 2012;60:1443-50.

74. Neumann S, Hue K, Semrau R, et al. Aldosterone and D-glucose stimulate the proliferation of human cardiac myofibroblasts in vitro. Hypertension 2002;39:756-60.
in cardiac hypertrophy and ventricular remodeling. Circ Res 2007;101:313-21.

105. Van Aelst LN, Voss S, Carai P, et al. Astrocyte prevents cardiac dilation and dysfunction after myocardial infarction through intact collagen strengthening. Circ Res 2015;116:245-36.

106. Naugle JE, Olson ER, Zhang X, et al. Type VI collagen induces cardiac myofibroblast differentiation: implications for postinfarction remodeling. Am J Physiol Heart Circ Physiol 2006;290: H233-30.

107. Roche PL, Filomeno KL, Bagchi RA, Czubryt MP. Intracellular signaling of cardiac fibroblasts. Compr Physiol 2015;5:721.

108. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol 2003;42:1845-60.

109. Ohtsu H, Frank GD, Utsunomiya H, Eguchi S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid Redox Signal 2005;7:1315-26.

110. Lijnen P, Papparella I, Petrov V, Semplicini A, Fagard R. Angiotensin II-stimulated collagen production in cardiac fibroblasts is mediated by reactive oxygen species. J Hypertens 2006;24:757-66.

111. Iglarz M, Touyz RM, Viel EC, Amiri F, Czubryt MP. Intracellular signaling of cardiac fibroblasts. Compr Physiol 2015;5:721.

112. Bageghni SA, Hemmings KE, Zava N, et al. Development of cardiac fibroblasts is dependent on the intronic CArG motif during the subacute stage of myocardial infarction. J Clin Invest 2014;124:2921-34.

113. Fu X, Khalil H, Kanisicak O, et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J Clin Invest 2018;128:2127-43.

114. Weng X, Yu L, Liang P, et al. Endothelial MRTF-A mediates angiotensin II induced cardiac hypertrophy. J Mol Cell Cardiol 2015;80:23-33.

115. Cheng TH, Cheng PY, Shih NL, Chen IB, Wang DL, Chen JJ. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am Coll Cardiol 2003;42:1845-60.
150. Clemente CF, Tornatore TF, Theizen TH, et al. Targeting focal adhesion kinase with small interfer- ing RNA prevents and reverses load-induced cardiac hypertrophy in mice. Circ Res 2007;101: 1339–48.

151. Adapaia RK, Thropll RJ, Luther DJ, et al. TRPV4 channels mediate cardiac fibroblast differ- entiation by integrating mechanical and soluble signals. J Mol Cell Cardiol 2013;54:45–52.

152. Harada M, Luo X, Qi XY, et al. Transient re- ceptor potential canonical-3 channel-dependent fibroblast regulation in atrial fibrillation. Circulation 2012;126:2051–64.

153. Abraham DM, Lee TE, Watson LJ, et al. The two-pore domain potassium channel TREK-1 mediates cardiac fibrosis and diastolic dysfunction. J Clin Invest 2012;128:4843–55.

154. Leinard G, Sauzeau V, Pardaou P. Small G proteins in the cardiovascular system: physiological and pathological aspects. Physiol Rev 2013;93:1659–720.

155. Shimizu T, Liao JK. Rho kinases and cardiac remodeling. Circ J 2016;80:1491–8.

156. Pfrommertuktul A, Tran L, Kompa A, et al. Effects of a Rho kinase inhibitor on pressure overload-induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008;294:H1804–14.

157. Shimizu T, Nara N, Chen P, et al. Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight 2017;2:39187.

158. Nishida M, Sato Y, Uemura A, et al. P2Y6 receptor-Galphalz13 signaling in cardiomyocytes triggers pressure overload-induced cardiac fibrosis. EMBO J 2008;27:3104–15.

159. Laroumante F, Douin-Echirand V, Pozzo J, et al. CD44 T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation 2014;129:2111–24.

160. Xang FL, Fang M, Uytzeye KE. Loss of JCAT- enin in resident cardiac fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat Commun 2017;8:712.

161. Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes. J Mol Cell Cardiol 2015;89:268–79.

162. Russo I, Cavaleri M, Huang S, et al. Protective effects of activated myofibroblasts in the pressure-overloaded myocardium are mediated through smad-dependent activation of a matrix-preserving program. Circ Res 2019;124: 1214–27.

163. Zheng J, Chen Y, Pat B, et al. Microarray identifies extensive downregulation of non- collagen extracellular matrix and profibrotic growth factors genes in chronic isolated mitral regurgitation in the dog. Circulation 2009;119: 2086–95.

164. Nagatomo Y, Carabello BA, Coker ML, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000;278: H151–61.

165. Chen Y, Pat B, Zheng J, et al. Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload. J Mol Cell Cardiol 2010;49:70–8.

166. Chace NY, Brower GL, Peterson JT, Janidi JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 2002;105:1983–8.

167. Childers RC, Sunyesz I, West TA, Cismowski MJ, Lucchesi PA, Gooch KJ. Role of the cysitokinetin in the development of a hypofibrotic cardiac fibroblast phenotype in volume overload heart failure. Am J Physiol Heart Circ Physiol 2018;316:H596–608.

168. Cox MJ, Hawkins UA, Hilt BD, Tyagi SC. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 2004;109:2123–8.

169. Cavaleri M, Wang J, Frangogiannis GN. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res 2014;164:323–35.

170. Russo I, Frangogiannis GN, Diabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2016;90:84–93.

171. Biemacka A, Cavaleri M, Wang J, et al. Smad3 signaling promotes fibrosis while preserving cardiac and aortic geometry in obese diabetic mice. Circ Heart Fail 2015;8:788–98.

172. Sorop O, Heinonen I, van Kranenburg M, et al. Multiple common co-morbidity produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening. Cardiovasc Res 2018;114:954–64.

173. Chen F, Chen D, Zhao X, et al. Interleukin-6 deficiency facilitates myocardial dysfunction during high fat diet-induced obesity by promoting lipotoxicity and inflammation. Biochim Biophys Acta 2017;1863:3128–41.

174. Alex L, Russo I, Holobrodovko V, Frangogiannis NG. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 2018;315:H3934–49.

175. Chen W, Frangogiannis GN. The role of inflammatory and fibrogenic pathways in heart failure associated with aging. Heart Fail Rev 2010;15:11–22.

176. Zhao J, Rendive R, Stewart JA. Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart. World J Diabetes 2014;5:860–7.

177. Gonzalez-Quesada C, Cavaleri M, Biemacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res 2013;113:1331–44.

178. Packer M. Derangements in adrenergic- adenosine signaling establish a neurohumoral basis for obesity-related heart failure with a preserved ejection fraction. Eur J Heart Fail 2018; 20:873–8.

179. Bujak M, Kweon HJ, Chatila K, Li N, Taffet G, Frangogiannis GN. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J Am Coll Cardiol 2008;51:1384–92.

180. Carnelliti P, Greve CR, LeGrice I, Kohl P. Fibroblast network in rat sinus venous node: structural and functional identification of homogeneous and heterogeneous cell coupling. Circ Res 2004;94:828–35.

181. Chang HY, Chi JT, Dudoit S, et al. Diversity, topographic differentiation, and positional mem- ory in human fibroblasts. Proc Natl Acad Sci U S A 2002;99:12877–82.

182. Franke WW, Schmid E, Osborn M, Weber K. Intermediate-sized filaments of human endothelial cells. J Cell Biol 1979;81:570–80.

183. Gabbiani G, Schmid E, Winter S, et al. Vascular smooth muscle cells differ from other smooth muscle cells: predominance of vimentin filaments and a specific alpha-type actin. Proc Natl Acad Sci U S A 1981;78:298–302.

184. Kong P, Christia P, Saxena A, Su Y, Frangogiannis GN. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am J Physiol Heart Circ Physiol 2013;305: H1363–72.

185. Shimazaki M, Nakamura K, Ji L, et al. Peri- ostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008;205: 295–303.

186. Takeda N, Manabe I, Uchino Y, et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254–65.

187. Snider P, Hinton RB, Moreno-Rodriguez RA, et al. Periostin is required for maturation and extracellular matrix stabilization of non-cardiomyocyte lineages of the heart. Circ Res 2008;102:752–60.

188. Santiago JJ, Dangerfield AL, Rattan SG, et al. Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 2010;239:1573–84.

189. Dobaczewski M, Bujak M, Zymek P, Ren G, Entman ML, Frangogiannis GN. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res 2006;324:475–88.

190. Dodapattar P, Gandhi C, Prakash P, et al. Fibronectin splice variants containing extra domain a promote atherosclerosis in mice through Toll-like receptor 4. Arterioscler Thromb Vasc Biol 2015;35:2391–400.

191. Chang ML, Chen JC, Alonso CR, Kombihit AR, Bissell DM. Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver. Proc Natl Acad Sci U S A 2004;101:18039–8.

192. Hu Y, Bock G, Wick G, Xu Q. Activation of PDGF receptor alpha in visceral smooth muscle cells by mechanical stress.FASEB J 1998;12: 1135–42.
193. Chen L, Acciani T, Le Cras T, Luttko C, Perl AK. Dynamic regulation of platelet-derived growth factor receptor alpha expression in alveolar fibroblasts during realveolarization. Am J Respir Cell Mol Biol 2012;47:517-27.

194. Goldsmith EC, Hoffman A, Morales MO, et al. Organization of fibroblasts in the heart. Dev Dyn 2004;230:787-94.

195. Chang Y, Guo K, Li Q, Li C, Guo Z, Li H. Multiple directional differentiation difference of neonatal rat fibroblasts from six organs. Cell Physiol Biochem 2016;39:157-71.

196. Squires CE, Escobar GP, Payne JF, et al. Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol 2005;39:699-707.

197. Zhang S, Bu X, Zhao H, et al. A host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis. J Pathol 2014;232:436-48.

198. Shyu KG, Chao YM, Wang BW, Kuan P. Regulation of discoidin domain receptor 2 by cyclic mechanical stretch in cultured rat vascular smooth muscle cells. Hypertension 2005;46:614-21.

199. Furtado MB, Costa MW, Pranoto EA, et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ Res 2014;114:1422-34.

200. Hudon-David F, Bouzeghrane F, Couture P, Thibault G. Thy-1 expression by cardiac fibroblasts: lack of association with myofibroblast contractile markers. J Mol Cell Cardiol 2007;42:991-1000.

201. Jurisic G, Iolyeva M, Proids ST, Halin C, Detmar M. Thymus cell antigen 1 (Thyl, CD90) is expressed by lymphatic vessels and mediates cell adhesion to lymphatic endothelium. Exp Cell Res 2010;316:2982-92.

202. Uchida S, De Gaspari P, Kostin S, et al. Scal-derived cells are a source of myocardial renewal in the murine adult heart. Stem Cell Rep 2013;1:397-410.

203. Braitsch CM, Kanisicak O, van Berlo JH, Molmenti JD, Yutzey KE. Differential expression of embryonic epicardial progenitor markers and localization of cardiac fibrosis in adult ischemic injury and hypertensive heart disease. J Mol Cell Cardiol 2013;65:108-19.

204. Schneider M, Kostin S, Stram CC, et al. S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 2007;75:40-50.

205. Tillmanns J, Hoffmann D, Habbaba Y, et al. Fibroblast activation protein alpha expression identifies activated fibroblasts after myocardial infarction. J Mol Cell Cardiol 2015;87:194-203.

206. Ruiz-Villabá A, Simón AM, Pogontike C, et al. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J Am Coll Cardiol 2015;65:2057-66.

207. Zhou B, Honor LB, He H, et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest 2011;121:1894-904.

208. van Amerongen MJ, Bou-Gharios G, Popa E, et al. Bone marrow-derived myofibroblasts contribute functionally to scar formation after myocardial infarction. J Pathol 2008;214:377-86.

209. Fujita J, Mori M, Kawada H, et al. Administration of granulocyte colony-stimulating factor after myocardial infarction enhances the recruitment of hematopoietic stem cell-derived myofibroblasts and contributes to cardiac repair. Stem Cells 2007;25:2760-9.

210. Kramann R, Schneider RK, DiRocco DP, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015;16:51-66.

**KEY WORDS** cytokines, extracellular matrix, fibroblast, infarction, remodeling